DIVERSIFIED HEALTHCARE T - DHC 6 1/4 02/01/46 (DHCNL) Stock Fundamental Analysis
NASDAQ:DHCNL - US25525P3055
17.7 USD
-0.12 (-0.67%)
17.7 USD
0 (0%)
DHCNL gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 129 industry peers in the Diversified REITs industry. DHCNL scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. DHCNL has a expensive valuation and it also scores bad on growth.
1. Profitability
1.1 Basic Checks
In the past year DHCNL has reported negative net income.
In the past year DHCNL had a positive cash flow from operations.
DHCNL had negative earnings in 4 of the past 5 years.
In multiple years DHCNL reported negative operating cash flow during the last 5 years.
1.2 Ratios
The Return On Assets of DHCNL (-6.03%) is worse than 84.50% of its industry peers.
Looking at the Return On Equity, with a value of -15.46%, DHCNL is doing worse than 79.84% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.03% | ||
| ROE | -15.46% | ||
| ROIC | N/A |
ROA(3y)-4.29%
ROA(5y)-2.48%
ROE(3y)-10.69%
ROE(5y)-6.22%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 17.80%, DHCNL is doing worse than 94.57% of the companies in the same industry.
In the last couple of years the Gross Margin of DHCNL has declined.
The Profit Margin and Operating Margin are not available for DHCNL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.8% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-20.05%
2. Health
2.1 Basic Checks
DHCNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DHCNL has been increased compared to 1 year ago.
The number of shares outstanding for DHCNL has been increased compared to 5 years ago.
The debt/assets ratio for DHCNL is higher compared to a year ago.
2.2 Solvency
Based on the Altman-Z score of 0.38, we must say that DHCNL is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.38, DHCNL is in line with its industry, outperforming 41.86% of the companies in the same industry.
DHCNL has a Debt/Equity ratio of 1.42. This is a high value indicating a heavy dependency on external financing.
DHCNL has a Debt to Equity ratio of 1.42. This is comparable to the rest of the industry: DHCNL outperforms 41.86% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.42 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.38 |
ROIC/WACCN/A
WACC6.93%
2.3 Liquidity
DHCNL has a Current Ratio of 3.37. This indicates that DHCNL is financially healthy and has no problem in meeting its short term obligations.
DHCNL's Current ratio of 3.37 is amongst the best of the industry. DHCNL outperforms 91.47% of its industry peers.
DHCNL has a Quick Ratio of 3.37. This indicates that DHCNL is financially healthy and has no problem in meeting its short term obligations.
DHCNL has a Quick ratio of 3.37. This is amongst the best in the industry. DHCNL outperforms 91.47% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.37 | ||
| Quick Ratio | 3.37 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 39.64% over the past year.
DHCNL shows a small growth in Revenue. In the last year, the Revenue has grown by 4.29%.
DHCNL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 7.53% yearly.
EPS 1Y (TTM)39.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
Revenue 1Y (TTM)4.29%
Revenue growth 3Y2.63%
Revenue growth 5Y7.53%
Sales Q2Q%3.05%
3.2 Future
The Earnings Per Share is expected to grow by 16.22% on average over the next years. This is quite good.
Based on estimates for the next years, DHCNL will show a small growth in Revenue. The Revenue will grow by 3.57% on average per year.
EPS Next Y28.82%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year3.93%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
DHCNL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year DHCNL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
DHCNL's Enterprise Value to EBITDA ratio is rather expensive when compared to the industry. DHCNL is more expensive than 94.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 28.41 |
4.3 Compensation for Growth
DHCNL's earnings are expected to grow with 16.22% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y16.22%
EPS Next 3YN/A
5. Dividend
5.1 Amount
DHCNL has a Yearly Dividend Yield of 1.06%. Purely for dividend investing, there may be better candidates out there.
With a Dividend Yield of 1.06, DHCNL pays less dividend than the industry average, which is at 6.16. 91.47% of the companies listed in the same industry pay a better dividend than DHCNL!
Compared to an average S&P500 Dividend Yield of 2.35, DHCNL's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.06% |
5.2 History
The dividend of DHCNL decreases each year by -45.60%.
DHCNL has been paying a dividend for over 5 years, so it has already some track record.
Dividend Growth(5Y)-45.6%
Div Incr Years0
Div Non Decr Years0
5.3 Sustainability
The earnings of DHCNL are negative and hence is the payout ratio. DHCNL will probably not be able to sustain this dividend level.
DP-3.36%
EPS Next 2Y16.22%
EPS Next 3YN/A
DIVERSIFIED HEALTHCARE T - DHC 6 1/4 02/01/46
NASDAQ:DHCNL (8/29/2025, 8:16:57 PM)
After market: 17.7 0 (0%)17.7
-0.12 (-0.67%)
Chartmill FA Rating
GICS SectorReal Estate
GICS IndustryGroupEquity Real Estate Investment Trusts (REITs)
GICS IndustryDiversified REITs
Earnings (Last)
Earnings (Next)
Inst Owners77.81%
Inst Owner ChangeN/A
Ins Owners0.41%
Ins Owner ChangeN/A
Market Cap4.27B
Analysts48
Price Target18.97 (7.18%)
Short Float %0%
Short Ratio0.36
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.06% |
Yearly Dividend0.04
Dividend Growth(5Y)-45.6%
DP-3.36%
Div Incr Years0
Div Non Decr Years0
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)25.74%
Min EPS beat(2)-71.02%
Max EPS beat(2)122.5%
EPS beat(4)2
Avg EPS beat(4)34.05%
Min EPS beat(4)-71.02%
Max EPS beat(4)122.5%
EPS beat(8)3
Avg EPS beat(8)16.12%
EPS beat(12)4
Avg EPS beat(12)5.38%
EPS beat(16)4
Avg EPS beat(16)-11.59%
Revenue beat(2)0
Avg Revenue beat(2)-0.26%
Min Revenue beat(2)-0.49%
Max Revenue beat(2)-0.04%
Revenue beat(4)1
Avg Revenue beat(4)-0.41%
Min Revenue beat(4)-2.43%
Max Revenue beat(4)1.32%
Revenue beat(8)2
Avg Revenue beat(8)-0.47%
Revenue beat(12)4
Avg Revenue beat(12)-0.38%
Revenue beat(16)4
Avg Revenue beat(16)-1.01%
PT rev (1m)11.52%
PT rev (3m)-13.97%
EPS NQ rev (1m)-2.5%
EPS NQ rev (3m)6.82%
EPS NY rev (1m)-14.73%
EPS NY rev (3m)-19.35%
Revenue NQ rev (1m)0.97%
Revenue NQ rev (3m)-2.81%
Revenue NY rev (1m)0.32%
Revenue NY rev (3m)-0.89%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 2.81 | ||
| P/FCF | N/A | ||
| P/OCF | 47.95 | ||
| P/B | 2.3 | ||
| P/tB | 2.3 | ||
| EV/EBITDA | 28.41 |
EPS(TTM)-0.67
EYN/A
EPS(NY)-0.68
Fwd EYN/A
FCF(TTM)-0.41
FCFYN/A
OCF(TTM)0.37
OCFY2.09%
SpS6.31
BVpS7.68
TBVpS7.68
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.03% | ||
| ROE | -15.46% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 17.8% | ||
| FCFM | N/A |
ROA(3y)-4.29%
ROA(5y)-2.48%
ROE(3y)-10.69%
ROE(5y)-6.22%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-6.33%
GM growth 5Y-20.05%
F-Score6
Asset Turnover0.32
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.42 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | 11.07 | ||
| Cap/Depr | 66.82% | ||
| Cap/Sales | 12.33% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 37.41% | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.37 | ||
| Quick Ratio | 3.37 | ||
| Altman-Z | 0.38 |
F-Score6
WACC6.93%
ROIC/WACCN/A
Cap/Depr(3y)103.34%
Cap/Depr(5y)92.72%
Cap/Sales(3y)19.78%
Cap/Sales(5y)17.46%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)39.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.57%
EPS Next Y28.82%
EPS Next 2Y16.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)4.29%
Revenue growth 3Y2.63%
Revenue growth 5Y7.53%
Sales Q2Q%3.05%
Revenue Next Year3.93%
Revenue Next 2Y3.57%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y38.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year374.57%
EBIT Next 3Y72.02%
EBIT Next 5YN/A
FCF growth 1Y71.19%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y283.65%
OCF growth 3YN/A
OCF growth 5Y-15.84%